Neuronetics (NASDAQ:STIM) Issues Earnings Results, Misses Expectations By $0.07 EPS

Posted by Amy Steele on Mar 4th, 2025

Neuronetics (NASDAQ:STIM – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.07), Zacks reports. Neuronetics had a negative return on equity of 141.24% and a negative net margin of 50.09%. Neuronetics updated its FY 2025 guidance to EPS and its Q1 2025 guidance to EPS.

Neuronetics Stock Performance

NASDAQ STIM opened at $4.26 on Tuesday. Neuronetics has a 52-week low of $0.52 and a 52-week high of $5.07. The company has a 50-day simple moving average of $2.85 and a 200 day simple moving average of $1.62. The company has a debt-to-equity ratio of 4.90, a quick ratio of 2.87 and a current ratio of 3.16. The company has a market capitalization of $129.28 million, a PE ratio of -3.46 and a beta of 2.17.

Insider Buying and Selling

In other news, CEO Keith J. Sullivan sold 40,992 shares of Neuronetics stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $3.28, for a total value of $134,453.76. Following the completion of the transaction, the chief executive officer now owns 1,283,362 shares in the company, valued at $4,209,427.36. This trade represents a 3.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Stephen Furlong sold 17,307 shares of Neuronetics stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $4.11, for a total transaction of $71,131.77. Following the completion of the transaction, the chief financial officer now owns 454,420 shares of the company’s stock, valued at $1,867,666.20. The trade was a 3.67 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 98,125 shares of company stock worth $348,876. Insiders own 9.80% of the company’s stock.

About Neuronetics

(Get Free Report)

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.